Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Recommendation of “Hold” from Brokerages

Simulations Plus, Inc. (NASDAQ:SLP) has received an average recommendation of “Hold” from the ten analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $25.00.

A number of research analysts recently weighed in on SLP shares. BTIG Research lowered Simulations Plus from a “buy” rating to a “neutral” rating in a report on Thursday, December 18th. TD Cowen reaffirmed a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. Wall Street Zen upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Zacks Research cut shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Finally, Citigroup reissued a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th.

Simulations Plus Stock Up 1.2%

Shares of NASDAQ:SLP opened at $11.96 on Thursday. The company has a market cap of $240.99 million, a P/E ratio of -3.74 and a beta of 1.18. Simulations Plus has a 52 week low of $11.09 and a 52 week high of $36.45. The company has a 50-day moving average price of $13.41 and a 200 day moving average price of $16.10.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.05). The business had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.05 million. Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.During the same quarter in the previous year, the firm posted $0.17 EPS. Analysts expect that Simulations Plus will post 1.09 EPS for the current year.

Institutional Investors Weigh In On Simulations Plus

A number of institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its stake in Simulations Plus by 26.6% in the 1st quarter. Royal Bank of Canada now owns 114,885 shares of the technology company’s stock valued at $2,817,000 after purchasing an additional 24,132 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Simulations Plus by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after purchasing an additional 390 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Simulations Plus in the first quarter valued at $255,000. Woodline Partners LP grew its holdings in Simulations Plus by 32.1% in the first quarter. Woodline Partners LP now owns 13,239 shares of the technology company’s stock valued at $325,000 after purchasing an additional 3,220 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Simulations Plus by 3.1% in the second quarter. Geode Capital Management LLC now owns 397,851 shares of the technology company’s stock valued at $6,943,000 after buying an additional 12,003 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.